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Abstract
Asthma is a chronic inflammatory airways disease in which respiratory viral infections frequently trigger exacerbations.
Current treatment of asthma with combinations of inhaled corticosteroids and long acting beta2 agonists improves asthma
control and reduces exacerbations but what impact this might have on innate anti-viral immunity is unclear. We
investigated the in vitro effects of asthma drugs on innate anti-viral immunity. Peripheral blood mononuclear cells (PBMC)
from healthy and asthmatic donors were cultured for 24 hours with the Toll-like receptor 7 agonist, imiquimod, or
rhinovirus 16 (RV16) in the presence of budesonide and/or formoterol. Production of proinflammatory cytokines and
expression of anti-viral intracellular signalling molecules were measured by ELISA and RT-PCR respectively. In PBMC from
healthy donors, budesonide alone inhibited IP-10 and IL-6 production induced by imiquimod in a concentration-dependent
manner and the degree of inhibition was amplified when budesonide and formoterol were used in combination. Formoterol
alone had little effect on these parameters, except at high concentrations (10
26 M) when IL-6 production increased. In RV16
stimulated PBMC, the combination of budesonide and formoterol inhibited IFNa and IP-10 production in asthmatic as well
as healthy donors. Combination of budesonide and formoterol also inhibited RV16-stimulated expression of the type I IFN
induced genes myxovirus protein A and 29,5 9 oligoadenylate synthetise. Notably, RV16 stimulated lower levels of type
Myxovirus A and oligoadenylate synthase in PBMC of asthmatics than control donors. These in vitro studies demonstrate
that combinations of drugs commonly used in asthma therapy inhibit both early pro-inflammatory cytokines and key
aspects of the type I IFN pathway. These findings suggest that budesonide and formoterol curtail excessive inflammation
induced by rhinovirus infections in patients with asthma, but whether this inhibits viral clearance in vivo remains to be
determined.
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Introduction
Asthma is a chronic inflammatory disease of the lower airways
affecting up to 300 million individuals worldwide and posing a
significant burden on health care systems in both western and
developing countries [1]. Asthma adversely affects patient quality
of life, productivity and absenteeism from school or work [2].
However, the major medical burden and health care costs of
asthma including morbidity and mortality occur during acute
exacerbations [3,4]. Up to 80% of episodes of acute asthma in
children and 70% in adults are attributed to respiratory viral
infection with rhinovirus being a major culprit [5,6,7,8].
Current asthma treatment usually includes a combination of
inhaled corticosteroids and long acting beta2 agonists. These
medications are effective at controlling symptoms of asthma and
they reduce but do not eliminate asthma exacerbations [9,10,11].
Moreover, the effects of these medications on host defence against
virus infections remains unclear. Induction of innate anti-viral
immunity is necessary for initiation for viral clearance and
recruitment of virus-specific adaptive immune responses
[12,13,14]. However, the excessive pro-inflammatory responses
in asthmatic individuals could contribute to the immunopathology
of acute episodes of asthma [15].
Initiation of immune responses against respiratory viral infection
involves both structural cells of the lungs and leukocytes recruited
from the circulation [16]. Although the respiratory mucosa is the
primary site of rhinoviral infection, migratory cells originating in the
bone marrow are likely to make a major contribution to host defence
against this virus [17]. There is increasing evidence that asthma is
associated with changes in the anti-viral function of blood leukocytes
[18,19,20,21]. Sampling the peripheral blood provides a way to
‘intercept and interrogate’ a variety of immune cells which are en route
to the lungs and regional lymph nodes. Furthermore, experimental
rhinovirus infections in asthmatics have shown a strong correlation
between in vitro responses of peripheral blood leukocytes to rhinovirus
and clinically relevant in vivo outcomes including asthma symptoms,
bronchial hyper-responsiveness and the extent of viral shedding
[22,23,24]. Whilst the effect of corticosteroids and long acting beta2
agonists on rhinovirus infected bronchial epithelial cells have been
investigated previously [25,26,27], there is little information regard-
ing the effects of these treatments on early innate immune responses
of peripheral blood leukocytes.
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of the glucocorticoid, budesonide, and the long acting beta2
agonist, formoterol, on innate immune responses to rhinovirus.
Rhinoviruses are single stranded RNA viruses that are likely to
have complex effects on host cells including interactions with host
defence molecules that detect viral nucleic acids. We have
previously shown that adolescents with asthma have a reduced
responses of peripheral blood leukocytes to agonists for the Toll-
like receptor for single stranded RNA (TLR7) [21]. Therefore we
first examined peripheral blood mononuclear cells that were
activated via TLR7 before conducting a series of experiments with
live rhinovirus strain 16 (RV16). Because differences in innate
interferon responses to rhinovirus between healthy and asthmatic
donors have been reported elsewhere [19,20,28], we examined the
in vitro effects of budesonide and formoterol on various aspects of
innate host immunity in healthy as well as asthmatic donors.
Results
Subject Characteristics
We previously observed differences in adaptive immunity to
rhinovirus between healthy premenopausal women and aged-
matched men [31]. However, innate immunity to rhinovirus was
not affected by age or sex in that study. Nonetheless, to eliminate
any potential gender-based confounding effects for the experi-
ments with RV16, 11 of 12 healthy donors and all asthmatic
PBMC donors were female. Healthy control and asthmatic donors
had similar body mass index (Table 1). The healthy donors were
slightly but significantly older than the asthmatic donors, but this is
unlikely to have a biological effect since most participants in both
groups were premenopausal in age. Asthmatic donors had mild to
moderate doctor-diagnosed asthma. Six of twelve asthmatics were
prescribed inhaled corticosteroids (budesonide or fluticasone
propionate in combination with formoterol or salmeterol) and
one was prescribed a nasal corticosteroid spray but none were
taking oral steroids. The asthmatic donors were all allergic to
house dust mites with or without allergic sensitivities to other
aeroallergens whereas the control group were all non-atopic
(Table 1).
Effects of budesonide and formoterol on TLR7 activated
PBMC from healthy donors
The initial experiments focused on TLR7-activated PBMC.
Cells from healthy donors were stimulated with the TLR7 agonist
IQ in the presence of increasing concentrations of budesonide and
formoterol. PBMC cultures stimulated with IQ produced large
amounts of the type I IFN-associated chemokine IP-10. Treatment
with high concentrations of budesonide (10
27–10
26 M) signifi-
cantly reduced IQ-induced IP-10 production with a maximum of
80% inhibition at 10
26 M budesonide (Figure 1A). Treatment
with budesonide alone had a stronger effect on the pro-
inflammatory cytokine IL-6 production with a concentration-
dependent reduction and reaching complete inhibition of IL-6 at
10
28 M budesonide (Figure 1B).
Formoterol also diminished IP-10 production induced by IQ
with significant inhibition of 76% observed at 10
26 M formoterol
(Figure 1C). In contrast, formoterol did not reduce IL-6
production stimulated by IQ (Figure 1D). In fact, there was a
2.8 fold enhancement of IL-6 production induced by IQ at
10
26 M formoterol, suggesting independent regulation of IP-10
and IL-6.
We next investigated the effects of combinations of budesonide
and formoterol at pharmacologically relevant concentrations. The
combination of budesonide and formoterol (10
28 M of each drug)
inhibited IQ-stimulated IP-10 production, whereas when tested
individually at the same concentrations, these drugs showed no
effect (Figure 2A). The reduction in IQ-stimulated IL-6 production
observed with budesonide treatment was further enhanced by
addition of formoterol (Figure 2B).
Effects of budesonide and formoterol on IFNa
production by RV16-stimulated PBMC from healthy and
asthmatic donors
Having shown that combinations of budesonide and formoterol
reduced TLR7-induced cytokine production, the following series
of experiments examined the effects of these drugs on RV16-
stimulated PBMC. RV16 induced IFNa production to a similar
extent in cells from both healthy and asthmatic donors (Figure 3A,
B). Budesonide (10
28 M) alone and in the combination with
formoterol (10
28 M) completely blocked IFNa production in-
duced by RV16, so it was impossible to determine if the
combination with formoterol had additional effects on IFNa
production. The degree of inhibition of IFNa achieved with
budesonide alone or in combination with formoterol was similar in
both healthy and asthmatic donors. Although formoterol alone
appeared to induce a modest reduction in RV16-stimulated IFNa
in PBMC from both healthy and asthmatic donors, this reduction
was not statistically significant.
Effects of budesonide and formoterol on molecules
downstream of IFNa
RV16 strongly induced production of similarly high levels of the
type I interferon responsive chemokine IP-10 in PBMC cultures of
healthy and asthmatic donors. In healthy donors, treatment with
Table 1. Patient characteristics of PBMC donors for experiments comparing the effects of asthma drugs on innate immunity to
RV16.
Variable Asthmatic donors Healthy donors
Number 12 12
Female 12 11
Age (median and IQ range) 30.00 (28.33–40.91) * 43.46 (33.54–50.81)
Body mass index (median and IQ range) 25.25 (21.50–27.08) 23.65 (21.01–30.53)
Sum skin prick diameters for 10 common aeroallergens (median and IQ range) 16.5 (10.25–37.1)** 0 (0–0)
*Difference between asthmatic and healthy donors by Mann Whitney U test (p=0.0106).
**Difference between asthmatic and healthy donors by Mann Whitney U test (p,0.0001). The most frequently recognised allergens were house dust mite (n=12), grass
pollen (n=6) cat dander (n=6) and Alternaria (n=4).
doi:10.1371/journal.pone.0027898.t001
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28 M) reduced RV16-induced IP-10 production by
78.1% (Figure 4A), whereas 10
29 M budesonide alone showed no
effect (Supplementary Figure S1A). This IP-10 production was
further reduced by addition of formoterol (10
28 M, Figure 4A),
although formoterol alone had no effect at this or higher
concentration (10
28 M, Figure 4A and 10
27 M, data not shown).
Budesonide (10
28 M) inhibited RV16-induced IP-10 to a
significantly greater extent in cultures from asthmatic individuals
than in cultures from healthy individuals (p=0.022). In fact the
degree of inhibition of IP-10 induced by budesonide in the
asthmatics was so complete that it was not possible to determine if
formoterol had additional inhibitory effects (Figure 4B). However,
with lower concentrations of budesonide (10
29 M), combination
with formoterol (10
28 M) further inhibited IP-10 synthesis by
RV16- stimulated PBMC from asthmatic donors (supplementary
Fig. S1B). Formoterol alone had no effect on RV-induced IP-10
(10
28 M, Figure 4B, and 10
27 M, data not shown).
MxA and OAS are two important anti-viral molecules down-
stream of type I IFN. RV16 strongly induced mRNA expression of
both MxA and OAS in cultures of PBMC from all healthy donors
(Figure 4 C, E). In healthy donors, budesonide alone, but not
formoterol, inhibited rhinovirus induction of MxA whereas neither
budesonide nor formoterol alone reduced rhinovirus-induced
expression of OAS. However, there was nearly complete inhibition
ofMxA (95.8%)andOASexpression(96.1%)bythe combination of
budesonide and formoterol.
In PBMC from asthmatic donors, RV16 also induced expression
of type I IFN stimulated genes (Figure 4 D, F), though the
magnitude of MxA and OAS expression was significantly less than
in PBMC from healthy donors (Table 2). Budesonide treatment of
PBMC from asthmatic donors significantly reduced RV16
induction of MxA expression (Figure 4D). The apparent reduction
in RV16-induced OAS by budesonide was not statistically
significant (Figure 4F). The combination of budesonide and
formoterol inhibited MxA and OAS induction by RV16 in PBMC
cultures of asthmatic donors by 78.8% and 73.5%, respectively, and
this was significantly lower degree of inhibition than in PBMC from
healthy donors (p=0.007 for MxA and p=0.0008 for OAS).
Figure 1. Dose dependent effects of budesonide and formoterol on markers of innate immunity induced by imiquimod (IQ). IP-10 (A,
C) and IL-6 (B, D) production by PBMC from 20 healthy female donors cultured with IQ in the presence of increasing concentrations (10
210–10
26 Ma s
indicated) of budesonide (Bud) and formoterol (Form). The background cytokine levels produced in unstimulated control cultures (median 69 pg/ml
IP-10 and 181 pg/ml IL-6) have been subtracted. Box and whisker plots show the median and interquartile range with 10
th–90
th percentile.
Differences between IQ-stimulated cultures and IQ-stimulated cultures with drugs were tested by Friedman ANOVA and Dunn’s multiple comparison
test (**, p,0.005; ***, p,0.001).
doi:10.1371/journal.pone.0027898.g001
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cytokines induced by RV16 in PBMC from healthy and
asthmatic donors
RV16 stimulation did not significantly induce IL-6 production
above that seen in unstimulated PBMC cultures (Supplementary
Figure S2). Nonetheless, the small amount of IL-6 produced was
completely abolished by treatment with budesonide (10
28 M) in
both healthy and asthmatic donors such that further effects of
formoterol (10
28 M) addition were not observed (Supplementary
Figure S2). At 10
29 M, budesonide did not significantly inhibit IL-
6 production with or without addition of formoterol (10
27 or
10
28 M) (data not shown). Formoterol alone at these concentra-
tions had no significant effect on RV-induced IL-6 production in
healthy or asthmatic donor PBMC (Supplementary Figure S2, and
data not shown).
Significant amounts of IL-8 and TNFa were not detected in
PBMC cultures exposed to RV16 for 24 h from either healthy or
asthmatic donors (data not shown).
Discussion
Rhinoviruses are common triggers for acute exacerbations of
asthma and are a significant cause of asthma morbidity and
mortality [3]. Inhaled corticosteroids and long acting beta2
agonists form the cornerstones of current asthma therapy [9,33],
and even in previously healthy individuals these agents are
sometimes used in an effort to reduce persistent airway symptoms
such as prolonged coughing after respiratory viral infections.
Combination therapy with corticosteroids and long acting beta2
agonists affords the advantage of limiting the dose of corticoste-
roids required to treat asthma [33]. However, it is not clear
Figure 2. Effect of combination of budesonide and formoterol on imiquimod (IQ)-induced markers of innate immunity. IP-10 (A) and
IL-6 (B) production by PBMC from eight healthy female donors were cultured with IQ with budesonide (Bud, 10
28 M) and/or formoterol
(Form,10
28 M). The background cytokine levels produced in unstimulated control cultures (median 211 pg/ml IP-10 and 238 pg/ml IL-6) have been
subtracted. Box and whisker plots show the median and interquartile range with 10
th–90
th percentile. Differences between IQ-stimulated cultures and
IQ-stimulated cultures with drugs were tested by Friedman ANOVA and Dunn’s multiple comparison test (**, p,0.005; ***, p,0.001).
doi:10.1371/journal.pone.0027898.g002
Figure 3. Effects of combination of budesonide and formoterol on IFNa-induced by rhinovirus. Cytokines produced by PBMC from
healthy (A) and asthmatic (B) donors cultured for 24 h with RV16 in the presence of budesonide (Bud, 10
28 M) and/or formoterol (Form,10
28 M) as
indicated. Box and whisker plots show median, interquartile range, and 10
th and 90
th percentiles for data from 12 donors in each subject group.
Significant differences by Friedman ANOVA and Dunn’s multiple comparison test for unstimulated versus RV16-stimulated cultures (+++,p ,0.005)
and between RV16-stimulated and RV16-stimulated cultures treated with budesonide and/or formoterol (***, p,0.001).
doi:10.1371/journal.pone.0027898.g003
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PBMC from healthy (A) and asthmatic (B) donors cultured for 24 h with RV16 in the presence of budesonide (Bud, 10
28 M) and/or formoterol (Form,
10
28 M) as indicated. Box and whisker plots show median, interquartile range, 10
th and 90
th percentiles for data. Quantitative RT-PCR analysis of anti-
viral genes MxA and OAS expression in healthy donors (C and E, n=8) and asthmatic donors (D and F, n=12). Significant differences by Friedman
ANOVA and Dunn’s multiple comparison test for unstimulated versus RV16-stimulated cultures (+++,p ,0.005) and between RV16 versus RV16 with
drugs were assessed by Friedman ANOVA and Dunn’s multiple comparison test (*, p,0.05; **, p,0.005, ***, p,0.001). To show the effects of the
drugs on gene expression the data for asthmatics is shown on a different scale to that from healthy donors.
doi:10.1371/journal.pone.0027898.g004
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capacity of circulating immune cells to mount an early innate
immune response to rhinovirus.
Here we observed that budesonide inhibited TLR7-induced
synthesis of IP-10 and IL-6 in PBMC, and that the degree of
inhibition was usually enhanced when budesonide was used in
combination with formoterol. Similarly, in RV16 stimulated
PBMC budesonide inhibited various aspects of innate anti-viral
responses, and mostly the degree of inhibition was enhanced when
budesonide was used in combination with formoterol. The
inhibitory effects of these drugs were seen in cultures of PBMC
from healthy as well as asthmatic donors.
Our observation that combination of budesonide and formo-
terol treatment inhibited early innate anti-viral immunity in
circulating leukocytes is consistent with previous research using
structural cells of the lung. In these studies budesonide and
formoterol or fluticasone propionate and salmeterol inhibited IP-
10 and IL-8 production induced by rhinovirus in cultured
bronchial epithelial cell lines and primary human epithelial cells
from healthy subjects [25,34]. Glucocorticoids have also been
shown to block rhinovirus-induced IP-10 production in airway
fibroblasts (Thomas and Bardin, personal communication). In
cultured airway smooth muscle, airway epithelial cells and lung
fibroblasts, combinations of these drugs exhibited synergistic
reduction in pro-inflammatory responses, chemokines and extra-
cellular matrix molecules involved in airway remodeling
[25,27,34,35,36,37].
Interestingly, we observed an increase in IQ-induced IL-6
production in the presence of extra high dose formoterol (10
26 M;
see Figure 1D). This finding is consistent with observations that
RV16-induced IL-6 production in the bronchial epithelial cell line
BEAS-2B was increased 2–3 fold by salmeterol (10
29 M and
10
28 M) [26], and that RV1b induction of IL-6 in bronchial
epithelial cell tended to increase by 40–50% at high doses of
formoterol (10
27 M and 10
26 M) [25]. These findings suggest that
use of salmeterol and formoterol in the absence of corticosteroids
may have pro-inflammatory effects. Also, the T helper 2 cell
promoting factor macrophage derived chemokine was enhanced
in bronchial epithelial cells in response to formoterol and
salmeterol suggesting that long acting beta2 agonists by themselves
could favour Th2 inflammation in the lung [38].
The contribution of rhinoviruses to acute exacerbations of
asthma has been well documented [5,6,7,8] but debate continues
as to whether the effects are directly due to the virus itself or
indirectly due to an aberrant host response to the virus. Following
experimental rhinovirus infection Message and colleagues report-
ed that the severity of lower airway symptoms was associated with
viral load [23]. In contrast, a longitudinal study of natural
rhinoviral infections in asthmatics indicated that severity of lower
respiratory tract symptoms was not related to viral load [39]. A
prospective study of cohabiting couples in UK (where one person
had atopic asthma and one was healthy) showed that whilst
asthmatics did not differ from healthy individuals in the frequency
of rhinovirus infections, the duration and severity of the infections
were increased in those with asthma [40]. Collectively, these
studies suggest that an aberrant immune response to rhinovirus
contributes to the induction and severity of symptoms following
rhinovirus infection in people with asthma, though how much of
this is due to asthma per se, and how much can be attributed to
medications used to treat asthma has not been investigated in
detail. Grunberg et al. found that pre-treatment with budesonide
decreased eosinophilic inflammation at six days post RV16
challenge but overall the mild airway inflammation induced by
RV16 was not affected, for better or worse, by budesonide [41].
However, in that study combination therapy with inhaled steroids
and long acting beta2 agonists was not examined, nor was there
any examination of early innate anti-viral immunity or viral
clearance [41].
Even though the combination of budesonide and formoterol
clearly inhibit aspects of anti-viral immunity, especially the type I
IFN pathway, the implications this has for airway inflammation
and host defence are not clear. Reduction of chemokines such as
IP-10 production would be expected to diminish recruitment of
activated T lymphocytes, key protagonists for immune responses
to rhinovirus. Reduced production of IFNb by bronchial epithelial
cells in asthma is thought to prevent effective anti-viral responses
and delay viral clearance [42,43]. Furthermore, PBMC from
asthmatics synthesise less IFNa2 when infected with respiratory
syncytial virus or Newcastle disease virus [20]. However, excessive
IP-10, a cytokine downstream of type I IFN, produced in response
to rhinovirus was associated with increased risk of asthma [42].
The primary aim of this study was to investigate the effects of
common asthma drugs on anti-viral innate immunity rather than
differences between healthy and asthmatic donors. Nonetheless,
while there were no detectible differences between healthy and
asthmatics donors in respect to IFNa production, RV16 induced
significantly lower expression of two important anti-viral mole-
cules, MxA and OAS, in asthmatics compared with healthy
subjects. This data is consistent with the notion that innate anti-
viral immunity is impaired in asthmatics [43,44]. Together it
appears that in asthma the dysregulated immunity to respiratory
viral infections is mediated not only by structural cells in the lung
but also by circulating leukocytes, possibly pDC [45,46].
The clinical consequences of the effects of budesonide and
formoterol on anti-viral immunity remain to be established.
Inhibition of inflammatory cytokine production and airway
inflammation is clearly a worthwhile therapeutic aim in asthma,
and there is compelling clinical evidence that these drugs are
beneficial in asthma. However, there remains a degree of concern
that inhibition of already impaired type I IFN might lead to
delayed viral clearance in some people with asthma. Some
investigators are already examining whether administration of type
I IFN might be beneficial in asthma. In a small study, 10 severe
steroid resistant asthmatics were afforded amelioration of their
asthma with intravenous low dose IFNa treatment suggesting a
protective role for type I IFN [47]. Moreover, type I IFN
treatment may provide benefits for patients with acute exacerba-
tions of asthma triggered by rhinoviral infection [48].
Budesonide and formoterol are capable of down regulating both
pro-inflammatory and type 1 IFN responses of peripheral blood
Table 2. Comparison of response to rhinovirus 16 between
healthy and asthmatic donors.
Parameter Healthy donors Asthmatic donors
IFNa (pg/ml) 155 (47–360) 213 (149–430)
IP-10 (pg/ml) 7956 (4056–9920) 7729 (5806–9375)
IL-6 (pg/ml) 297 (150–412) 295 (150–1702)
MxA (cDNA fold
induction)
16.2 (1.8–30.1) 3.85 (2.7–6.8)*
OAS (cDNA fold
induction)
4.6 (3.1–16.7) 2.1 (1.5–5.9)**
Data is presented as median (interquartile range).
*MxA expression was significantly lower in asthmatic donors p=0.0182.
*OAS expression was significantly lower in asthmatic donors p=0.039.
doi:10.1371/journal.pone.0027898.t002
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tance of the type I IFN response in protection against rhinovirus in
healthy and asthmatic donors and the complex interactions
between migratory immune cells derived from the circulation
and structural cells of the respiratory tract, there is now a clear
need for further in vivo studies examining the effects of budesonide
and formoterol therapy upon viral clearance and duration of
symptoms following rhinovirus challenge in patients with asthma.
Methods
Study participants
Volunteers were recruited from the Respiratory Clinic, Princess
Alexandra Hospital and from normal healthy laboratory and
healthcare workers. The subjects of the study were skin prick
tested to a panel of ten common areoallergen extracts including
house dust mite, grass and ragweed pollens, molds and cat dander
(Holister Stier, Spokane, WA, USA). Participants completed a
detailed questionnaire documenting symptoms of lung disease and
atopic disorders such as allergic rhinitis and eczema, and current
medication use. All asthmatic subjects had a prior diagnosis of
asthma confirmed by a doctor and a history of typical mild to
moderate asthma symptoms within the last 12 months. All healthy
control subjects were free of respiratory symptoms and had
negative allergen skin prick tests. The study was conducted in
accordance to the Declaration of Helsinki and was approved by
the Princess Alexandra Hospital and the University of Queensland
Human Research Ethics Committees. Informed written consent
was obtained from each subject.
Peripheral blood mononuclear cells were isolated from
heparinised blood using Lymphoprep (Axis-shield, Oslo, Norway)
and cryopreserved for subsequent experiments as previously
described [21].
Culture conditions
Ohio HeLa cells and the major group rhinovirus strain RV16
were kindly donated by Professor Phil Bardin (Monash Medical
Centre, Melbourne, Australia). RV16 was propagated in Ohio
HeLa cells and purified over a sucrose gradient as previously
described [29,30]. Imiquimod (IQ, Invivogen, San Diego, CA,
USA), formoterol and budesonide (kindly donated by Astra
Zeneca, Macclesfield Cheshire SK10NA, United Kingdom) were
dissolved in dimethylsulfoxide at 10
22 M and frozen in aliquots
until use. The final concentration of DMSO in the cultures was
negligible; at the highest concentration of budesonide and
formoterol at 10
26 M, there was 0.001% v/v DMSO). Duplicate
wells with 2.5610
5 PBMC per well at a density of 1610
6 per
millilitre were cultured in RPMI media supplemented with
penicillin, streptomycin, glutamate, 2-mercaptoethanol and 10%
foetal calf serum. Cells were cultured with and without IQ (1 mg/
ml) or rhinovirus 16 (RV16) at a multiplicity of infection of one.
To replicate cultures with IQ or RV16 various combinations of
budesonide and formoterol from 10
210 Mt o1 0
26 M were added.
Cultures were incubated at 37uC with 5% CO2. Cell pellets from
cultures harvested at 6 hour were stored in RNA-protect (Qiagen,
Hilden, Germany) until RNA was extracted. Supernatants from
cells cultured for 24 hour were harvested for cytokine quantifica-
tion by ELISA.
ELISA
IP-10 (CXCL10), IL-6, TNFa and IL-8 ELISAs were
performed using commercially available paired antibodies and
recombinant cytokines (Becton Dickenson, Franklin Lakes, NJ,
USA) and IFNa was assayed via ELISA kit (PBL Interferon
Source, Piscataway, NJ, USA) according to the manufacturer’s
instructions. The lower limits of detection of these assays were as
follows: IP10, 3.9 pg/ml; IL-6 and TNFa, 4.0 pg/ml; IFNa,4.9
and IL-8 7.8 pg/ml.
Quantitative Real Time PCR. RNA was extracted using
RNeasy or RNeasy plus Spin kit and reverse transcribed using
Quantitect reverse transcription kit (Qiagen), according to
manufacturer’s instructions. Real Time (RT-) PCR was
performed with Quantitect SYBR green PCR mix (Qiagen).
The expression of mRNA transcripts for Myxovirus protein A
(MxA) and 29,59-oligoadenylate sythetase (OAS) were determined
taking into account the efficiency of amplification of values
normalized to expression of the reference Ubiquitin containing
enzyme D2 gene as described [31,32].
Statistics
Statistical analysis was performed using SPSS 18 (IBM SPSS
Inc., Chicago, IL, USA). Data was assessed for normality by
Kolmogorov-Smirnov test. Differences between IQ or RV16
stimulated cultures with and without drugs were analysed by non-
parametric Friedman ANOVA with Dunn’s pairwise multiple
comparison tests, with p,0.05 considered significant. When
values for responses to stimuli were normally distributed then
differences between healthy and asthmatic donors were assessed by
a Student’s T test.
Supporting Information
Figure S1 Effects of other concentrations of combined budeso-
nide and formoterol on IP-10 induced by rhinovirus. Cytokines
produced by PBMC from age- and body mass index-matched
female healthy (A) and asthmatic (B) donors cultured for 24 h with
RV16 in the presence of budesonide (Bud, 10
29 M) and/or
formoterol (Form,10
28 M) as indicated. Box and whisker plots
show median, interquartile range, and 10
th and 90
th percentiles for
data from 12 donors in each subject group. Significant differences
by Friedman ANOVA and Dunn’s multiple comparison test for
unstimulated versus RV16-stimulated cultures (++,p ,0.005) and
for RV16 versus RV16 with drugs (*, p,0.05).
(TIF)
Figure S2 Effects of combination of budesonide and formoterol
on IL-6 induced by rhinovirus. Cytokines produced by PBMC
from age- and body mass index-matched female healthy (A) and
asthmatic (B) donors cultured for 24 h with RV16 in the presence
of budesonide (Bud, 10
28 M) and/or formoterol (Form, 10
28 M)
as indicated. Data shown as median, interquartile range and 10
th
and 90
th percentiles for data from 12 donors. Significant
differences by Friedman ANOVA and Dunn’s multiple compar-
ison test for RV-stimulated cultures versus RV-stimulated cultures
with drugs (*, p,0.05; ***, p,0.001).
(TIF)
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